WCLC 2026

WCLC 2026
September 12-15, 2026
Seoul, South Korea

World Conference on Lung Cancer.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (2)

    Primary Results from Phase 3 EVOKE-03/KEYNOTE D46: Sacituzumab Govitecan + Pembrolizumab in PD-L1 TPS ≥ 50% Metastatic NSCLC

    • Author(s): Mountzios, G
    • trodelvy
    • Oncology
    • Trodelvy
    • NSCLC
    • SG
    • Sacituzumab
    • Combination
    • Pembro
    • Lung

    Long-Term Safety of Sacituzumab Govitecan + Pembrolizumab in Patients with Metastatic NSCLC from EVOKE-02

    • Author(s): Chul Cho, B
    • trodelvy
    • Oncology
    • EVOKE-02
    • Trodelvy
    • NSCLC
    • SG
    • Sacituzumab
    • Combination
    • Pembro
    • Lung